Testosterone Transdermal System Shortage
Last Updated: March 13, 2023
Status: Current
Products Affected - Description
-
- Androderm transdermal patch, Allergan (AbbVie), 2 mg/24 hour, carton, 60 count, NDC 00023-5990-60 - discontinued
- Androderm transdermal patch, Allergan (AbbVie), 4 mg/24 hour, carton, 30 count, NDC 00023-5992-30 - discontinued
Reason for the Shortage
-
- Allergan (Abbvie) has discontinued Androderm transdermal patches.
- Allergan (Abbvie) was the sole supplier of testosterone transdermal patches.
Available Products
-
- There are no presentations available
Updated
Created March 13, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.